Table 1 Patient characteristics
From: Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Number | 35 |
Age (years) | 71.4 ± 11.3 |
Gender (male: female) | 25: 7 |
Cause of heart failure | |
Hypertension | 17 (49%) |
Ischemia | 9 (26%) |
Valve disease | 6 (17%) |
Cardiomyopathy | 3 (8%) |
Risk factors | |
Hypertension | 27 (77%) |
Dyslipidemia | 29 (83%) |
Hyperuricemia | 19 (54%) |
Chronic kidney disease | 24 (69%) |
Obesity | 18 (51%) |
Metabolic syndrome | 19 (54%) |
Past smoker | 13 (37%) |
Current smoker | 0 |
Classification of heart failure | |
HFrEF | 2 (6%) |
HFpEF | 33 (94%) |
Medication | |
Oral hypoglycemic agent | |
Alpha-glucosidase inhibitor | 5 (14%) |
Biguanide | 5 (14%) |
DPP4 inhibitor | 16 (46%) |
Sulfonylurea | 9 (26%) |
Thiazolidine derivatives | 1 (3%) |
No medication | 15 (43%) |
ACE-inhibitor | 2 (6%) |
Aldosterone blocker | 16 (46%) |
ARB | 13 (37%) |
Beta blocker | 28 (80%) |
Calcium antagonist | 10 (29%) |
Renin-inhibitor | 1 (3%) |
Furosemide | 13 (37%) |
Tolvaptan | 1 (3%) |
Statin | 28 (80%) |
XO inhibitor | 17 (49%) |